Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma
This study has been completed.
Study NCT00219258   Information provided by Novartis

First Received on September 12, 2005.   Last Updated on November 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Treatment of Bone Metastases
Additional conditions recognized in this trial
Bone Marrow Diseases
Bone Neoplasms
Multiple Myeloma
Neoplasm Metastasis
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Bone Diseases
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Musculoskeletal Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplastic Processes
Paraproteinemias
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
Zoledronic acid
Additional drug interventions recognized in this trial
Diphosphonates
More general drug interventions related to this trial
Bone Density Conservation Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services